Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens

Legislation slowly wending its way through states and in Washington could mean increased payments to drugstore chains like CVS Health, Walgreens, Walmart and independent pharmacies across the country.

Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens

In the latest trading session, CVS Health (CVS) closed at $44.36, marking a +1.32% move from the previous day.

Why CVS Health (CVS) Outpaced the Stock Market Today

Green Dot

New Collaboration with Green Dot Enables Cash Deposits at Over 7,500 CVS Pharmacy Locations AUSTIN, Texas and SAN FRANCISCO , Dec. 20, 2024 /PRNewswire/ -- Varo Bank , the first all-digital nationally chartered bank in the U.S., today announced a collaboration with Green Dot Corporation  (NYSE: GDOT) and CVS Health  (NYSE: CVS) to enable deposits for no fee for millions of Varo Bank customers at over 7,500 participating CVS Pharmacy locations nationwide. 1  Utilizing Green Dot's embedded finance platform (Arc) and expansive money movement network, the "Green Dot Network," Varo customers can now deposit cash at participating CVS Pharmacy locations 2  with zero fees.

Varo Bank Introduces Zero Fee Cash Deposits at Participating CVS Locations

Aviat Networks

Charles River Laboratories

DLH Hlds

Foot Locker

Valaris Ltd

Foot Locker, CVS Health and Charles River Laboratories are among hard-hit stocks that look ready to recover.

Tax-related selling is hitting these 7 stocks — but their loss could be your gain

Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.

Reasons to Ratain CVS Stock in Your Portfolio Now

CVS Health Corp (NYSE:CVS) has been accused by the US Department of Justice of violating the Controlled Substances Act (CSA) and the False Claims Act (FCA). A lawsuit filed in Rhode Island claims CVS knowingly knowingly filled prescriptions for opioids that lacked legitimate medical purposes.

CVS contributing to US opioid crisis, Justice Department alleges

WASHINGTON--(BUSINESS WIRE)--Today, the United States Department of Justice (DOJ) announced it has filed a complaint in intervention in a whistleblower lawsuit brought under the False Claims Act (FCA) by Baron & Budd against CVS Pharmacy for their harmful opioid dispensing practices. Adding to allegations made in the whistleblower lawsuit, the DOJ complaint alleges that CVS Pharmacy knowingly filled millions of unlawful prescriptions for controlled substances that lacked a legitimate medica.

DOJ Files Complaint in Intervention in Baron & Budd Whistleblower Lawsuit Against CVS Pharmacy

The U.S. Department of Justice on Wednesday announced a lawsuit accusing CVS of filling and billing federal health insurance programs for illegal opioid prescriptions.

US accuses CVS of filling, billing government for illegal opioid prescriptions

Archer-Daniels-Midland Company

ConocoPhillips

Energy Transfer LP Unit

Halliburton

Johnson & Johnson

Coca-Cola

Lockheed Martin

Altria

Omnicom Group

PepsiCo

Prologis

Southern Company

AT&T

Exxon Mobil

The June/July, 2024 Fortune Magazine revealed 500 biggest U.S. companies by-revenue and profits. Arnold-research focused on 66 December industry-leaders using YCharts 12/13/24 data for Profits from 63. Those 63 Fortune 500 industry leaders (F500IL) were segmented into 21 business sectors ranging (alphabetically) from aerospace/defense to wholesalers. By yield, MO topped-all F500IL. Top-ten Yields from PEP, PLD, SO, XOM, ADM, T, UPS, CVS, ET, & MO, averaged 4.71% in December.

Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy

Healthpeak Properties Inc

Realty Income Corp

Starbucks

We focused on building two positions over the last year: Realty Income and Starbucks. AT&T slashed its dividend several years ago in an effort to shore up its balance sheet. Starbucks has rebounded well, ever since it dropped in the $70s late in 2023 and early 2024.

Bert's November 2024 Dividend Income Summary

Cigna

UnitedHealth Group

Shares in major healthcare companies fell yesterday after president-elect Donald Trump made comments that he wanted to “knock out” prescription drug industry middlemen. The fall makes this yet another week since the killing of UnitedHealth CEO Brian Thompson that the business practices of companies that operate America's private healthcare system have come under increased scrutiny.

UnitedHealth, CVS, and Cigna stock prices take another hit after Trump says he's going to ‘knock out' drug industry middlemen

CVS's stock was headed to its biggest monthly loss in 23 years, as Donald Trump vowed to “knock out” the pharmacy middleman.

CVS's stock seeing worst month in decades as drug seller gets criticism from both parties

AbbVie

Bristol-Myers

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

CVS Health (CVS) stock price continued its strong downward trend as the company's woes accelerated. Most recently, it has dropped in the last three consecutive weeks, moving to a low of $46.60, its lowest level since March 2020.

CVS Health stock price has crashed: buy this dip

Health insurance companies have been in the limelight lately after the shooting of Brian Thompson, the CEO of the medical insurance arm of UNH. Furthermore, a news report suggesting that a bipartisan group of lawmakers may introduce legislation to force health insurance companies to divest their pharmacy business has raised concerns among investors.

Is CVS Stock A Better Pick Over UNH Stock?

WOONSOCKET, R.I. , Dec. 16, 2024 /PRNewswire/ -- CVS Health Corporation ("CVS Health" or the "Company," NYSE: CVS) announced today the applicable Reference Yields and Total Consideration (each as summarized in the tables below) to be paid in connection with the previously announced cash tender offer (the "Maximum Tender Offer" ) for the maximum principal amount of the following series of Maximum Tender Offer Notes (as defined below) for which the aggregate purchase price, not including Accrued Interest (as defined below), payable in respect of such Maximum Tender Offer Notes, does not exceed $1,774,423,242.62  (such maximum purchase price, the "Maximum Tender Offer Amount"): its 2.700% Senior Notes due 2040, the 3.875% Senior Notes due 2047 issued by its wholly-owned subsidiary Aetna Inc. ("Aetna"), its 4.250% Senior Notes due 2050, the 4.125% Senior Notes due 2042 issued by Aetna, its 4.125% Senior Notes due 2040, its 2.125% Senior Notes due 2031, its 1.875% Senior Notes due 2031, its 5.050% Senior Notes due 2048, the 4.500% Senior Notes due 2042 issued by Aetna and its 1.750% Senior Notes due 2030 (together, the "Maximum Tender Offer Notes").

CVS Health Corporation Announces Pricing of Maximum Tender Offer

Eli Lilly

Pfizer

Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.

Insurer stocks fall after Trump says 'we're going to knock out the middleman'

WOONSOCKET, R.I. , Dec. 16, 2024 /PRNewswire/ -- CVS Health Corporation ("CVS Health" or the "Company," NYSE: CVS) announced today the early results of the previously announced cash tender offer (the "Maximum Tender Offer") for the maximum principal amount of the following series of Maximum Tender Offer Notes (as defined below) for which the aggregate purchase price, not including Accrued Interest (as defined below), payable in respect of such Maximum Tender Offer Notes, does not exceed $1,774,423,242.62 (such maximum purchase price, the "Maximum Tender Offer Amount"): its 2.700% Senior Notes due 2040, the 3.875% Senior Notes due 2047 issued by its wholly-owned subsidiary Aetna Inc. ("Aetna"), its 4.250% Senior Notes due 2050, the 4.125% Senior Notes due 2042 issued by Aetna, its 4.125% Senior Notes due 2040, its 2.125% Senior Notes due 2031, its 1.875% Senior Notes due 2031, its 5.050% Senior Notes due 2048, the 4.500% Senior Notes due 2042 issued by Aetna and its 1.750% Senior Notes due 2030 (together, the "Maximum Tender Offer Notes").

CVS Health Corporation Announces Early Results of Maximum Tender Offer and Election of Early Settlement

CVS plunged to $49, trading at a forward P/E of 8-9x, well below its 16x historical average. PBM segment contributes 46% of CVS income; fears of reform impact led to significant market overreaction. A 25% PBM profitability cut reduces EPS to ~$4, implying a fair value of $60 (with a P/E of 15x).

CVS's Sell-Off May Be Overblown

Shares of CVS Health Corporation  CVS are trading lower on Thursday. This move could break important support.

Stock Of The Day: Historic Technical Analysis Lesson In CVS

New legislation targeting pharmacy benefit managers (PBMs) could cut CVS Health earnings in half. CVS stock fell, along with UnitedHealth and Cigna.

CVS Health Hits 11-Year Low; PBM Legislation Could Slash Earnings By 50%, Says Analyst

The pharmacy stock would stand by itself if Walgreens goes private. Wall Street weighs in on the worth of the company's parts.

CVS Might Just Be the Last Drugstore Stock. Should It Be Broken Up?

Centene

Elevance Health Inc

Humana

Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.

Health care stocks fall as lawmakers, patients push for changes to their business models

Shares of health insurers such as UnitedHealth and CVS Health fell on Wednesday after a Wall Street Journal report said a bipartisan group of lawmakers were set to introduce legislation to break up pharmacy-benefit managers.

Health insurer stocks fall as WSJ says lawmakers set to break up pharmacy-benefit managers

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

News for CVS Health Stock (CVS)